Development
Thermo Fisher Scientific Inc.
TMO
$414.90
$0.17980.04%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 3.43% | 14.72% | -18.21% | -41.81% | -4.95% |
| Total Depreciation and Amortization | -1.06% | 1.79% | 2.27% | 0.00% | 24.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,333.33% | -400.00% | 134.15% | 3,700.00% | -95.37% |
| Change in Net Operating Assets | 65.36% | 97.55% | 15.43% | -75.20% | 408.28% |
| Cash from Operations | 6.77% | 24.63% | 0.79% | -66.89% | 41.92% |
| Capital Expenditure | 26.36% | 39.31% | 43.87% | 28.44% | 33.81% |
| Sale of Property, Plant, and Equipment | 83.33% | 1,550.00% | -66.67% | 200.00% | -45.45% |
| Cash Acquisitions | -- | -91,000.00% | -- | -6,660.00% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.26% | -100.00% | -254.67% | 75.00% | 375.00% |
| Cash from Investing | 28.38% | -116.70% | -5.73% | -368.96% | 97.19% |
| Total Debt Issued | -29.01% | 1,641.71% | 46.06% | 64.06% | -80.10% |
| Total Debt Repaid | -- | -647.00% | 14.03% | 67.99% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -50.00% | -890.10% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -16.24% | -14.41% | -15.38% | -13.59% | -13.59% |
| Other Financing Activities | -30.00% | 156.25% | -89.19% | 158.82% | -74.68% |
| Cash from Financing | -159.72% | 1,328.48% | 23.57% | 17.55% | -71.76% |
| Foreign Exchange rate Adjustments | -96.00% | 65.57% | 115.38% | 68.69% | 18.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -65.57% | 193.00% | 60.30% | -194.22% | 174.14% |